EmCyte, maker of platelet-rich plasma and progenitor stem cell biologics equipment, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Progenikine Concentrating System for adipose lipoplasty. The system's 510(k) is cleared for all medical procedures involving the harvesting and transferring of autologous adipose tissue.
The system is designed for pure extraction and centrifugal preparation of adipose concentrate at the point of care. It is equipped with an innovation that permits the full and complete removal of oil contaminants and effluent residuals while securing a concentrated adipose treatment sample.
“We’re excited about the vast benefits of the Progenikine Concentrating System,” says Patrick Pennie, president and CEO of EmCyte. “It’s a powerful biologic with a wide application base allowing it to be a viable choice for a multitude of procedures. Progenikine has taken its place on the stage of regenerative biologics and provides practitioners with a superior option for adipose concentrate.”
For more information, visit www.emcyte.com.
